| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income, net | 1,453 | 1,643 | ||
| Net loss | -18,234 | -21,006 | ||
| Unrealized gain (loss) on available-for-sale investments, net of tax | 6 | -177 | ||
| Comprehensive loss | -18,228 | -21,183 | ||
| Net loss per sharebasic | -0.47 | -0.55 | ||
| Net loss per sharediluted | -0.47 | -0.55 | ||
| Weighted-average common stock outstandingbasic | 38,560,464 | 38,461,619 | ||
| Weighted-average common stock outstandingdiluted | 38,560,464 | 38,461,619 | ||
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)